Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNotes PayablesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CNBX Pharmaceuticals (CNBX) Other Non-Current Liabilities (2018 - 2020)

CNBX Pharmaceuticals (CNBX) has disclosed Other Non-Current Liabilities for 3 consecutive years, with $2.8 million as the latest value for Q2 2020.

  • For the quarter ending Q2 2020, Other Non-Current Liabilities changed 0.0% year-over-year to $2.8 million, compared with a TTM value of $2.8 million through May 2020, changed 0.0%, and an annual FY2019 reading of $2.8 million, up 3003.35% over the prior year.
  • Other Non-Current Liabilities was $2.8 million for Q2 2020 at CNBX Pharmaceuticals, roughly flat from $2.8 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $2.8 million in Q4 2018 and bottomed at $89722.0 in Q3 2018.
  • Average Other Non-Current Liabilities over 3 years is $2.4 million, with a median of $2.8 million recorded in 2018.
  • Peak annual rise in Other Non-Current Liabilities hit 3003.35% in 2019, while the deepest fall reached 0.0% in 2019.
  • Year by year, Other Non-Current Liabilities stood at $2.8 million in 2018, then fell by 0.0% to $2.8 million in 2019, then grew by 0.0% to $2.8 million in 2020.
  • Business Quant data shows Other Non-Current Liabilities for CNBX at $2.8 million in Q2 2020, $2.8 million in Q1 2020, and $2.8 million in Q4 2019.